SYNI Synvista Therapeutics (PNK) 16 Feb 2026: Down 99.999% and setup for bounce

SYNI stock hit $0.000001 USD on the PNK exchange on 16 Feb 2026 after a -99.9988% intraday move, creating an extreme oversold profile we track for a potential short-term bounce. We see this move driven by ultra-low liquidity, a tiny market cap of $3.00 USD, and headline-free clinical development noise. For traders using an oversold bounce strategy, the trade is about size, clear stops, and watching thin-volume spikes that can produce sharp, short-lived rallies.

SYNI stock snapshot and key metrics

Synvista Therapeutics, Inc. (SYNI) trades on PNK in the United States with current last print $0.000001 USD, a market cap of $3.00 USD, and 2,586,000 shares outstanding. Yesterday’s previous close was $0.083 USD, volume today is 5,229 versus an average volume of 260, and relative volume sits at 20.11, signaling a one-off liquidity event. Reported EPS is -7.657 and the reported PE is a negative figure consistent with deep losses.

SYNI stock technicals and oversold bounce setup

Technical indicators on raw data show RSI and MACD readings near 0.00, which reflect the practical reality that technicals are unreliable when a tape is effectively at zero; instead focus on order book depth and volume spikes for intraday entries. An oversold bounce setup here relies on a tight entry, a predefined stop-loss, and targets sized to quick profit-taking because the stock’s low float and thin bid can cause rapid mean-reversion moves.

SYNI stock fundamentals and clinical catalysts

Synvista Therapeutics, Inc. is a small healthcare company developing ALT-2074 and alagebrium in Phase II trials for diabetes-related cardiovascular risks and diastolic heart failure, which remain the only near-term potential catalysts. The company lists 9 full-time employees, headquarters in Parsippany, New Jersey, and no recent headline catalysts; without clear trial updates or financing, fundamentals alone do not support a durable rebound.

Meyka AI rates SYNI with a score out of 100

Meyka AI rates SYNI with a score of 62.42 out of 100, Grade B — HOLD; this grade factors in S&P 500 benchmark comparison, sector and industry performance, financial growth, key metrics, forecasts, and analyst consensus. This grade highlights that while the stock shows technical oversold characteristics, the underlying fundamentals and liquidity constraints keep risk elevated; grades are informational and not investment advice.

SYNI stock risks, liquidity and trading strategy

Key risks for SYNI stock are extreme illiquidity, potential delisting or reverse split activity, and the lack of recent revenue or robust cash disclosures; traders should size positions to a fraction of a portfolio and use limit entries and strict stops. For an oversold bounce strategy we recommend small position sizing, staggered profit targets, and monitoring for any corporate filings or clinical updates that can change direction quickly.

SYNI stock price forecasts and targets

Meyka AI’s forecast model projects a short-term scenario price target of $0.01 USD and a cautious mid-term target of $0.10 USD if clinical news or financing emerges; at the current price of $0.000001 USD the short-term target implies an upside of approximately 999,900.00% and the mid-term target implies approximately 9,999,900.00%. Forecasts are model-based projections and not guarantees; given the tiny base price, percentage moves are extreme and sensitive to tiny absolute changes.

Final Thoughts

SYNI stock currently shows an extreme oversold profile after a collapse to $0.000001 USD on PNK, driven largely by liquidity shocks rather than fresh clinical readouts. Our oversold bounce view is tactical: a disciplined, small-sized trade can capture short-term mean reversion when volume spikes above the avg 260 shares; however, the underlying fundamentals — EPS -7.657, negative PE, and a market cap of $3.00 USD — leave the long-term outlook uncertain. Meyka AI’s forecast model projects a short-term bounce to $0.01 USD (implied upside ~999,900.00%) but emphasizes that these projections are model-based and not guarantees. Traders considering SYNI stock should prioritize risk controls, watch for filings or trial updates, and treat any rally as potentially transient unless accompanied by real financing or clinical confirmation. As an AI-powered market analysis platform, Meyka AI flags this name for high reward and very high risk outcomes.

FAQs

Why did SYNI stock collapse to nearly zero?

SYNI stock fell due to a liquidity-driven sell-off, a tiny float, and no recent positive clinical or financing news; the volume spike shows forced selling rather than fundamental improvement.

Can SYNI stock stage an oversold bounce?

An oversold bounce is possible given the low base and spiking relative volume, but trades must be small, use tight stops, and watch for fleeting price moves without new positive catalysts.

What is Meyka AI’s short-term projection for SYNI stock?

Meyka AI’s forecast model projects a short-term target of $0.01 USD for SYNI stock, noting this is a model projection and not a guarantee; risk of loss remains high.

What trading rules should I use with SYNI stock?

Use strict position sizing, limit orders, predefined stop-loss levels, and intraday profit-taking rules; avoid allocating significant capital given liquidity and delisting risks.

Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.